IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics
Masato Sasaki(Daiichi-Sankyo (Japan)), Tak W. Mak(University Health Network), Stefanie S. Schalm(Agios Pharmaceuticals (United States)), María E. Figueroa(University of Miami), Christiane B. Knobbe‐Thomsen(German Cancer Research Center), Ari Melnick(Cornell University), Jillian Haight(University Health Network), Andrew Wakeham(Ontario Institute for Cancer Research), Dwayne L. Barber(University of Toronto), Wanda Y. Li(Ontario Institute for Cancer Research), Carl Virtanen(University Health Network), Joshua Munger(University of Rochester Medical Center), Juan Carlos Zúñiga‐Pflücker(University of Toronto), Pamela S. Ohashi(University Health Network), Shinsan M. Su(Agios Pharmaceuticals (United States)), Roxanne Holmes(Sunnybrook Health Science Centre), Isaac S. Harris(University of Rochester Medical Center), Dirk Brenner(University of Luxembourg), Anne Brüstle(Australian National University), Guido Reifenberger(Düsseldorf University Hospital), Annick You-Ten(Ontario Institute for Cancer Research), Evan Lind(Oregon Health & Science University)
Cited by 510
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
|European Journal of Immunology|2019|1k
Regulation of tumour necrosis factor signalling: live or let die
|Nature reviews. Immunology|2015|994